CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Visterra, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Visterra, Inc.
1 Kendall Square
Suite B3301
Phone: (617) 498-1070p:617 498-1070 Cambridge, MA  02139-1604  United States Fax: (617) 498-1073f:617 498-1073

This company was Merged or Acquired on 8/31/2018.
On 2/10/2017, Visterra Inc. filed a Registration Withdrawal Request of its Form S-1 (File No. 333-208874) with the SEC. The Registration Statement is being withdrawn due to market conditions unfavorable for the Company to conduct its initial public offering and the Company’s determination that the registration of its securities is not in the best interests of the Company at this time.
This is a Subsidiary, click here for the Parent Company

Business Summary
Visterra, Inc. is a United States-based biotechnology company. The Company uses its Atomic Interaction Network analysis to identify disease targets and design effective therapeutics. The Company’s technology is based on its Hierotope Platform, which identifies an area, or epitope, on the target protein, glycoprotein or glycan that is fundamental to its structure and function. The Company’s Hierotope Platform is able to identify the region of the protein, or epitope, which is structurally constrained, and thus prevented from mutation over time or under immunological or therapeutic pressure. Its technology for creating potent and therapeutics is powered by the Company’s computational tools and techniques, the core of which is called Atomic Interaction Network (AIN) analysis.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
-Yes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201612/31/2015YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Alan L.Crane
President, Chief Executive Officer, Director Brian J.Pereira 57 7/15/2013 7/15/2013
Founder, Board Member RamSasisekharan
Chief Financial Officer and Chief Operating Officer David A.Arkowitz
Vice President, Research ZacharyShriver

General Information
Number of Employees: 43 (As of 6/30/2016)
Outstanding Shares: 16,296,214 (As of 9/30/2016)
Stock Exchange: NASD
Federal Tax Id: 320225657
Fax Number: (617) 498-1073


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, November 19, 2019